Stocks:
5,168
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.78T
24h Vol:
$10.16B
Dominance:
MSFT:4.81%
Stocklytics Platform
Asset logo  MRK
Merck & Co
MRK
64 / 100
High Growth
S&P500
$130.75arrow_drop_down0.17%-$0.23

Performance History

Stocklytics logo
Key Stats
Open$131.67
Prev. Close$130.99
EPS0.91
Dividend$3.00
Next Earnings DateJul 2, 2024
Dividend Yield %2.35%
Market Cap$332.27B
PE Ratio143.89
LOWHIGH
Day Range130.78
132.78
52 Week Range99.14
133.10
Ratios
P/B Ratio8.48
Revenue$59.87B
Operating M. %42.47%
Earnings$365.00M
Earnings Growth %-97.49%
EBITDA Margin %35.43%
ROE %5.31%
EPS0.91

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$804.85
24H (%)arrow_drop_up2.76%
24H ($)$21.67
MARKET CAP$744.33B
PRICE$522.71
24H (%)arrow_drop_up1.05%
24H ($)$5.48
MARKET CAP$476.05B
PRICE$150.86
24H (%)arrow_drop_down0.27%
24H ($)-$0.41
MARKET CAP$364.05B
PRICE$162.60
24H (%)arrow_drop_down1.19%
24H ($)-$1.95
MARKET CAP$293.87B

About Merck & Co (MRK)

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Sector
Healthcare
Industry
Drug Manufacturers—General
CEO
Mr. Robert M. Davis J.D.
Headquarters
Rahway
Employees
67000
Exchange
NYSE
add Merck & Co  to watchlist

Keep an eye on Merck & Co

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Merck & Co 's (MRK) price per share?

The current price per share for Merck & Co (MRK) is $130.94. The stock has seen a price change of -$0.05 recently, indicating a -0.04% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Merck & Co (MRK)?

For Merck & Co (MRK), the 52-week high is $133.1, which is 1.65% from the current price. The 52-week low is $99.14, the current price is 32.08% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Merck & Co (MRK) a growth stock?

Merck & Co (MRK) has shown an average price growth of 0.41% over the past three years. It has received a score of 81 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Merck & Co as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Merck & Co (MRK) stock price performance year to date (YTD)?

As of the latest data, Merck & Co (MRK) has a year-to-date price change of 15.63%. Over the past month, the stock has experienced a price change of 3.15%. Over the last three months, the change has been 2.8%. Over the past six months, the figure is 27.52%. Looking at a longer horizon, the five-year price change stands at 66%.

help
Is Merck & Co (MRK) a profitable company?

Merck & Co (MRK) has a net income of $365M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 73.31% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 42.47% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $59.87B, with a revenue growth rate of 0.99%, providing insight into the company's sales performance and growth. The gross profit is $43.89B. Operating income is noted at $2.98B. Furthermore, the EBITDA is $7.54B.

help
What is the market capitalization of Merck & Co (MRK)?

Merck & Co (MRK) has a market capitalization of $332.28B. The average daily trading volume is 6.32M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level